Origin and prognostic value of circulating KRAS mutations in lung cancer patients

O. Gautschi, B. Huegli, A. Ziegler, M. Gugger, J. Heighway, D. Ratschiller, P. C. Mack, P. H. Gumerlock, H. J. Kung, R. A. Stahel, D. R. Gandara, D. C. Betticher

研究成果: 雜誌貢獻文章

65 引文 斯高帕斯(Scopus)

摘要

Because of the current controversy on the origin and clinical value of circulating KRAS codon 12 mutations in lung cancer, we screened 180 patients using a combined restriction fragment-length polymorphism and polymerase chain reaction (RFLP-PCR) assay. We detected KRAS mutations in 9% plasma samples and 0% matched lymphocytes. Plasma KRAS mutations correlated significantly with poor prognosis. We validated the positive results in a second laboratory by DNA sequencing and found matching codon 12 sequences in blood and tumor in 78% evaluable cases. These results support the notion that circulating KRAS mutations originate from tumors and are prognostically relevant in lung cancer.
原文英語
頁(從 - 到)265-273
頁數9
期刊Cancer Letters
254
發行號2
DOIs
出版狀態已發佈 - 九月 8 2007
對外發佈Yes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

指紋 深入研究「Origin and prognostic value of circulating KRAS mutations in lung cancer patients」主題。共同形成了獨特的指紋。

  • 引用此

    Gautschi, O., Huegli, B., Ziegler, A., Gugger, M., Heighway, J., Ratschiller, D., Mack, P. C., Gumerlock, P. H., Kung, H. J., Stahel, R. A., Gandara, D. R., & Betticher, D. C. (2007). Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Letters, 254(2), 265-273. https://doi.org/10.1016/j.canlet.2007.03.008